Skip to content

Study on the efficacy of traditional Chinese medicine in the treatment of nonarteritis anterior ischemic optic neuropathy

Multicenter randomized clinical trial of acupuncture in the treatment of chronic non-arteritic anterior ischemic optic neuropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000062
Enrollment
Unknown
Registered
2022-06-28
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonarteritic anterior ischemic optic neuropathy

Interventions

Sham acupuncture group :Sham acupuncture +Oral Methylcobalamin Tablets
Acupuncture group :Acupuncture + Oral Methylcobalamin Tablets

Sponsors

Eye Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria of western medicine and traditional Chinese medicine; (2) Age 50-80 years old, gender is not limited; (3) The course of the disease is 1-5 months; if the patient has the onset of both eyes successively and the onset time of both eyes is 1-5 months, the latter eye will be selected and included in the group; (4) Good control of blood pressure and blood sugar; (5) Not participating in other clinical trials during treatment; (6) Patients volunteered to participate in this research.

Exclusion criteria

Exclusion criteria: (1) Arteritis anterior ischemic optic neuropathy is excluded; (2) Hormone therapy has been used within one week before enrollment; (3) Suffering from other eye diseases or diopter exceeding ±6.00DS; (4) Patients with recurrent NAION in one eye; (5) Combined with other eye diseases; (6) suffering from mental or neurological diseases; (7) Dysfunction of important organs such as the heart, liver and kidney; (8) Suffering from malignant tumor; (9) Pregnant or lactating women; (10) Participating in other relevant clinical investigators; (11) Patients who refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
vision ;

Secondary

MeasureTime frame
optical coherence tomography;visual field;

Countries

China

Contacts

Public ContactWang Ying

Eye Hospital of China Academy of Chinese Medical Sciences

wangyingtcm@163.com13581515068

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026